Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder

Robert M Bilder, Sandra K Loo, James J McGough, Fiona Whelan, Gerhard Hellemann, Catherine Sugar, Melissa Del'Homme, Alexandra Sturm, Jennifer Cowen, Grant Hanada, James T McCracken, Robert M Bilder, Sandra K Loo, James J McGough, Fiona Whelan, Gerhard Hellemann, Catherine Sugar, Melissa Del'Homme, Alexandra Sturm, Jennifer Cowen, Grant Hanada, James T McCracken

Abstract

Objective: Psychostimulants are partially effective in reducing cognitive dysfunction associated with attention-deficit/hyperactivity disorder (ADHD). Cognitive effects of guanfacine, an alternative treatment, are poorly understood. Given its distinct action on α2A receptors, guanfacine may have different or complementary effects relative to stimulants. This study tested stimulant and guanfacine monotherapies relative to combined treatment on cognitive functions important in ADHD.

Method: Children with ADHD (n = 182; aged 7-14 years) completed an 8-week, double blind, randomized, controlled trial with 3 arms: d-methylphenidate (DMPH), guanfacine (GUAN), or combination treatment with DMPH and GUAN (COMB). A nonclinical comparison group (n = 93) had baseline testing, and a subset was retested 8 weeks later (n = 38). Analyses examined treatment effects in 4 cognitive domains (working memory, response inhibition, reaction time, and reaction time variability) constructed from 20 variables.

Results: The ADHD group showed impaired working memory relative to the nonclinical comparison group (effect size = -0.53 SD unit). The treatments differed in effects on working memory but not other cognitive domains. Combination treatment improved working memory more than GUAN but was not significantly better than DMPH alone. Treatment did not fully normalize the initial deficit in ADHD relative to the comparison group.

Conclusion: Combined treatment with DMPH and GUAN yielded greater improvements in working memory than placebo or GUAN alone, but the combined treatment was not superior to DMPH alone and did not extend to other cognitive domains. Although GUAN may be a useful add-on treatment to psychostimulants, additional strategies appear to be necessary to achieve normalization of cognitive function in ADHD.

Clinical trial registration information: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder; https://ichgcp.net/clinical-trials-registry/NCT00429273" title="See in ClinicalTrials.gov">NCT00429273.

Keywords: attention-deficit/hyperactivity disorder; cognition; guanfacine; stimulant; working memory.

Conflict of interest statement

Disclosure: Drs. Loo, Hellemann, Sugar, Del’Homme, Cowen, Ms. Whelan, Ms. Sturm, and Mr. Hanada report no biomedical financial interests or potential conflicts of interest.

Copyright © 2016 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Source: PubMed

3
Subscribe